These findings establish that hepatocellular carcinoma metabolic phenotypes constitute pivotal molecular determinants of TACE treatment response, with genes including HK2 and AFP serving as potential prognostic biomarkers for TACE sensitivity prediction. The gene discussed is AFP; the disease is hepatocellular carcinoma.